Yield10 Bioscience Begins 2021 Field Test and Seed Scale Up Program
July 13 2021 - 8:30AM
Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience
company, today announced it has completed planting of its 2021
Field Test and Seed Scale Up program at all contracted sites in the
United States, Canada, and Argentina.
Yield10’s 2021 Field Test program is designed to test several
varieties of elite Camelina, as well as seed yield and oil content
traits. In addition, Yield10 has contracted with a seed company for
scale up of three Camelina varieties to enable larger scale
plantings in 2022. With increasing focus on Camelina products,
Yield10 is completing initial field testing of a promising
CRISPR-edited trait which has shown up to a 4% increase in seed oil
content plus a positive impact on seed yield in canola. Yield10
expects that harvest of seeds across the field tests will be
completed in third quarter 2021, and that data will be received
starting in fourth quarter 2021.
“Our 2021 field program is our most extensive program to date,
involving 16 locations, and is expected to generate data to guide
the advancement of our novel traits,” said Dr. Kristi Snell, Ph.D.,
Chief Science Officer of Yield10. “We are also conducting seed
scale up activities with three Camelina lines intended to enable
future planting at the 100-to-1000-acre scale, as well as for
producing oil and meal for customer sampling. The objective for our
field testing and seed scale up program is to build an industry
leading elite Camelina germplasm, and to further differentiate our
Camelina using proprietary traits. We believe these traits have the
potential to enhance the value of the crop by increasing seed yield
and oil content and by producing value-add products including
omega-3 nutritional oil and PHA bioplastic.”
Yield10 2021 Field Test and Seed Scale Up Program
Summary:
- Elite Camelina Germplasm: Yield10 is
evaluating over 20 base germplasm lines including wildtype, doubled
haploid, herbicide tolerant and disease resistant varieties at more
than 10 sites across the U.S., Canada, and Argentina. Yield10 is
also conducting a multi-acre scale up of a doubled haploid Camelina
line and a disease resistant Camelina line in the U.S. under a
collaboration with a seed company.
- Camelina/CRISPR E3902: Yield10 is conducting a
multi-acre scale up of CRISPR genome edited trait E3902 in the
U.S., as E3902 has demonstrated consistent increases in oil content
in the field over the previous two growing seasons. USDA-APHIS does
not consider this line to be regulated pursuant to 7 CFR part
340.
- Camelina/C3014 and C3015 (PHA): Yield10 is
scaling up its two best PHA Camelina lines at sites in the U.S. and
Canada. Yield10 designed traits C3014 and C3015 to produce PHA
bioplastic as a third seed product in Camelina. Results of field
tests in 2020 achieved a proof-of-concept milestone for a
plant-based route of production for PHA.
- Canola/CRISPR: Yield10 is evaluating canola
lines with a CRISPR genome-edited trait which has shown an increase
in oil content in canola. In recent greenhouse studies, this trait
has resulted in a 4% increase in seed oil production plus increased
seed yield. This trait is being tested in the U.S. with a seed
company. USDA-APHIS does not consider this line to be regulated
pursuant to 7 CFR part 340.
- Camelina/Novel Yield Traits: Yield10 will test
additional novel performance traits generated using the Company’s
GRAIN platform in the 2021 Field Test program at sites in the U.S.
and Canada.
During these field tests, Yield10 is monitoring key agronomic
and growth parameters of the plants throughout the growth period.
Yield10 also plans to evaluate seed yield, oil content, PHA
content, and/or other parameters of the traits as appropriate after
seed harvest. The field tests are designed to generate data on the
performance of the novel traits under field conditions, and to
advance the development of the traits toward commercialization.
The seed scale up program is designed to generate field-grown
seed for subsequent field studies as well as to build seed
inventory to enable planting at increasing scale. In addition, seed
from the program may be used to produce meal, oil, and PHA for
customer sampling and other business development purposes.
About Yield10 Bioscience
Yield10 Bioscience, Inc. is an agricultural bioscience company
that is using its differentiated trait gene discovery platform, the
“Trait Factory”, to develop improved Camelina varieties for the
production of proprietary seed products, and to discover high value
genetic traits for the agriculture and food industries. Our goals
are to efficiently establish a high value seed products business
based on developing superior varieties of Camelina to produce
feedstock oils, nutritional oils, and PHA bioplastics, and to
license our yield traits to major seed companies for
commercialization in major row crops, including corn, soybean, and
canola. Yield10 is headquartered in Woburn, MA and has an Oilseeds
Center of Excellence in Saskatoon, Canada.
For more information about the company, please visit
www.yield10bio.com, or follow the Company on Twitter, Facebook and
LinkedIn.
(YTEN-G)
Safe Harbor for
Forward-Looking Statements
This press release contains forward-looking statements which are
made pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking
statements in this release do not constitute guarantees of future
performance. Investors are cautioned that statements in this press
release which are not strictly historical, including, without
limitation, statements regarding the Company’s intentions with
regard to plans to conduct field tests with Camelina and canola in
2021, the plans to conduct seed scale up with Camelina in 2021 and
winter 2021-2022, the results and outcome of, and information
gathered from, those tests, the ability to use the results of the
tests in future studies or licensing activities, whether the
Company’s traits will increase seed yield or boost oil content or
PHA, whether the field tests will generate data on the performance
of the novel traits under field conditions, whether the field tests
will advance the development of the traits toward
commercialization, whether the seed scale up program will generate
seed for subsequent field studies or seed inventory to enable
planting at increasing scale, whether seed from the program may be
used to produce meal, oil, and PHA for customer sampling and other
business development purposes, and expectations with regard to the
timing of harvesting the plants and obtaining results of the field
tests, constitute forward-looking statements. Such forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those
anticipated, including weather and weather-related events that may
impact the progress or results of the field trials and the risks
and uncertainties detailed in Yield10 Bioscience's filings with the
Securities and Exchange Commission. Yield10 assumes no obligation
to update any forward-looking information contained in this press
release or with respect to the matters described herein.
Contacts: Yield10 Bioscience:Lynne H. Brum,
(617) 682-4693, LBrum@yield10bio.com
Investor Relations: Bret Shapiro, (561) 479-8566,
brets@coreir.comManaging Director, CORE IR
Media Inquiries: Eric Fischgrund, eric@fischtankpr.com FischTank
PR
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Apr 2023 to Apr 2024